Zhou et al. reported that dapagliflozin improves endothelial dysfunction by restoring eNOS activity and NO bioavailability, and decreasing ROS levels via Sirt1 activation in oxidative stress-stimulated endothelial cells [121]. Here, SIRT1 is linked to endothelial dysfunction.